Harmony Biosciences Holdings Inc’s filing revealed that its Former Officer JEFFREY G DIERKS acquired Company’s shares for reported $0.2 million on Jun 10 ’25. In the deal valued at $35.98 per share,5,615 shares were bought.
Then, JEFFREY G DIERKS bought 9,844 shares, generating $350,083 in total proceeds.
Before that, JEFFREY G DIERKS bought 2,292 shares. Harmony Biosciences Holdings Inc shares valued at $80,427 were divested by the Former Officer at a price of $35.09 per share.
A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. H.C. Wainwright began covering HRMY with “Buy” recommendation on December 17, 2024.
Price Performance Review of HRMY
On Tuesday, Harmony Biosciences Holdings Inc [NASDAQ:HRMY] saw its stock jump 0.41% to $32.06. Over the last five days, the stock has lost -2.55%. Harmony Biosciences Holdings Inc shares have risen nearly 11.28% since the year began. Nevertheless, the stocks have fallen -6.83% over the past one year. While a 52-week high of $41.61 was reached on 01/21/25, a 52-week low of $26.47 was recorded on 04/09/25.
Levels Of Support And Resistance For HRMY Stock
The 24-hour chart illustrates a support level at 31.66, which if violated will result in even more drops to 31.26. On the upside, there is a resistance level at 32.46. A further resistance level may holdings at 32.86.
How much short interest is there in Harmony Biosciences Holdings Inc?
A steep rise in short interest was recorded in Harmony Biosciences Holdings Inc stocks on 2025-05-30, growing by 0.13 million shares to a total of 3.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 3.25 million shares. There was a rise of 3.83%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 10, 2024 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $56 price target.
